Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19
Easy To Use And Produce
09 Sep 2020 INTERVIEWS
... Destiny and SporeGen have been awarded a grant of £800,000 from Innovate UK to fund the majority of the £1m ($1.3m) needed for the initial SPOR-COV program. The preclinical work will be undertaken in collaboration with the University of Liverpool, while manufacturing and formulation development will be carried out by Huro, based in Vietnam.
The aim is to start human clinical studies in the next 18 months but Cutting noted that the partners "will have to make a decision about the best way to move forward, " either taking the classic (and lengthy) drug development route or adopting a medical food intervention approach.
Destiny CEO Neil Clark told Scrip, "We're pragmatic about how the product could be delivered, and would have no problem going down the regulated food medicine route or the classic drug development route. Once we produce the data, it will be very interesting to see how the regulatory environment develops. There's been a lot of amazing rapid approvals of studies in the vaccine eld so if we can deliver a strong data package, are we going to get similar support? The prole of this product is much safer than the vaccines."
Clark stressed that "we're both high-quality R&D companies, based on validated science and we're well funded now to kick on. I think a year from now, potentially it will be very interesting to see where we're going with the data set."
Cutting concluded by saying that "there are long-term benets to having a simple solution yet we live in a world where everything has to be sophisticated. It's one of the big problems with science. If I were to speak to [UK prime minister] Boris Johnson and show him a simple approach or very sophisticated approach, he'd focus on the sophisticated approach. It is human nature."
The deal met with approval from Equity Development analyst Andy Smith who issued a note saying that Destiny "have always had a microbiome tilt with their most advanced product, topical XF-73 (exepornium chloride), being developed for the prevention of post-operative infections." With the SporeGen deal, "they have taken this even further to encompass the two hot-button issues in anti-infectives: the microbiome and coronavirus infections."
He added, "This positive development plays to Destiny’s strengths in topical (nasal) administration,
preventative indications, as well as the cost-effective management of its earlier-stage pipeline…the
development of SporeGen’s technology as a preventative therapy for COVID-19 has many advantages
over traditional vaccines."
Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19
Easy To Use And Produce
09 Sep 2020 INTERVIEWS
The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.
The search for a vaccine dominates the headlines but two UK biotechs are taking a prophylactic approach to develop a nasal spray that targets the innate immune system, which has the potential to develop COVID-19 protection within a few days of treatment.
Antimicrobial specialist Destiny Pharma plc has teamed up with SporeGen Ltd. to co develop its SPOR-COV product which contains a proprietary formulation of Bacillus bacteria that will be administered nasally via a spray. Unlike traditional vaccination, SPOR COV focuses on innate immunity and having provided 100% protection in preclinical models of inuenza virus, the companies believe this could also apply to coronavirus infection.
SporeGen CEO Simon Cutting told Scrip that the vaccines being developed for COVID 19 are injectable "but you acquire this disease in your respiratory tract and normally you vaccinate at the sites where you want to develop protection, which is the mucosal route. My prediction is that the vaccines being developed at the
moment probably will protect you from death and will have some level of protection, but they won't protect you from being colonized. If people are colonized by the virus, they can then spread it to other people, so vaccines are unlikely to prevent the disease from disseminating across the world."
He noted, "In the absence of seeing any data at this moment in time, no one really knows what's going to happen. Our approach is like taking an amplier and switching up the frequency like in the movie Spinal Tap where if you boost immunity, you're more protected." Cutting said elderly people "seem to be most susceptible to this disease and they are more immune compromised, so maybe you just need a simple solution for boosting immunity and that's something we've been working on."
COVID-19 is the fourth pandemic in 20 years "and there's a high probability that in the future, we will have future pandemics," he noted, saying that "we need something that does not require cold-chain refrigeration, could be manufactured very simply and could be stockpiled." While the science behind the project is sophisticated, "we have a very pragmatic and very simple approach, which we already know works for pandemic u."
SPOR-COV "is very much a disruptive technology, it's rather like Uber," Cutting said. "This is a pandemic and we need an approach that works now." ...
10th Sep 2020 7:00 am RNS Notice of Results
Notice of Interim Results
Brighton, United Kingdom - 10 September 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), will announce its financial results for the six months ended 30 June 2020 on Thursday, 17 September 2020.
A webcast for analysts will take place at 09:30am BST.
"Technical Analysis for DEST - Destiny Pharma Plc"
"Grade Last Price % Change Price Change
grade A 57.3 -2.88% -1.70"
"ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up"
"Destiny Pharma PLC (DEST)"
"57.30 -1.70 -2.88%"
"DEST Technical Analysis"
Moving Averages: BUY Buy (12) Sell (0)
Technical Indicators: STRONG BUY Buy (8) Sell (0)"
Destiny Pharma already have a nasal apply drug for hospital patients to protect from MRSA and other hospital bugs. The new joint venture and Innovate UK funding for COVID immunity could and should be rocket fuel for the share price. A £25m market cap is crazy, if this was Nasdaq listed we would be at £250m plus. Vox podcast 26 minutes in today ****************************/articles/chairman-of-aberdeen-standard-investments-martin-gilbert-plus-alan-green-glen-goodman-e731cd6
Now that this collaboration has been announced we have two very interesting and exciting propositions in preventative medicine. PM is likely to gain more traction and pharma focus will surely shift from cures and treatments to being able to ward something off in the first place. (afterall a responsible government would surely want to avoid putting its populaton through the ravages of MRSA (the most dangerous woman in the world) and Cov19 - if it can be avoided. Rather like the blonde buffoon trying get the nation to lose weight and the orange one wanting to disinfect all known life processes...... I may mock but prevention is certainly the way ahead. (Who knows with this latest tie-up and DEST's fasttrack with the FDA they may well be a sitting duck at this price?)
Really interesting share this one, it had been off my radar until today... Surely at £25m market cap it's materially mispriced? Based on how low the free float is, combined with positive recent momentum, I think a short term target of £1 is readily achievable. Also always positive to see a share finish the day on a high.
SF - thanks for the heads-up on the broker 250p target price ... I now see that reiteration.
The 197p valuation which I mentioned is from Equity Development and their new note of earlier this morning.
I'll be delighted to see the DEST sp reaching either of those two three digit numbers!
Welcome news today on the grant and potential covid treatment, this isn’t even DEST’s lead asset so a nice bonus if it comes good.
Shares are very tightly held, over 70% of which directors hold approx 20%. Won’t take much for this to run to 100p +
ONE of my gems gla very happy slowly slowly
they are almost damned by the amount of shares in issue. Some Delboys wont think its a bargain unless its in the units not realising its all relative to amount of shares in issue.........
£2.50 from house broker Fcap. - FWIW
Many seem unaware of DEST and its 197p valuation.
Top riser for 2day
DEST is forecasting peak US sales for its XF-73 drug of $US 1 billion.
In contrast, DEST's current market cap. at 45.1p is just £19.78 million.
3rd Mar 2020 7:00 am RNS Clinical and Business Update
" ... The Company's ongoing Phase 2b clinical trial of its lead asset, XF-73 (exeporfinium chloride) nasal gel, is testing XF-73 as a novel drug for the prevention of post-surgical infections caused by Staphylococcus aureus (SA), including the superbug variant methicillin-resistant S. aureus (MRSA). US, EU and WHO surgical guidelines are recommending this type of treatment to tackle nasal SA/MRSA bacterial carriage in all high risk surgeries and the Company forecast peak US sales of $US 1 billion driven by the appropriate use of XF-73 in millions of eligible surgical procedures. ..."
EDITORS' PICK|3,588 views|Aug 4, 2020,07:00am EDT
Could Drug-Resistant Bacteria Cause The Next Pandemic?
Louis Metzger IV Contributor
I am an infectious disease biochemist and entrepreneur.
... Aided by modern humans' mobility and by climate change, bacterial pathogens endanger everyone's health. They are legion, varied, and constantly mutating. ...
The germs of some of history's worst pandemics, bacteria still imperil human health on a massive scale. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, has afflicted humanity for millennia. Twenty-five percent of the world's population may carry a latent form of the disease. Killing 1.5 million annually, it is the leading cause of infectious disease death. Strains of Mycobacterium tuberculosis have mutated to become resistant to many or all antibacterial drugs.
The aptly-named Yersinia pestis caused the Bubonic plague, which ravaged Eurasia and Africa, periodically flaring into catastrophic pandemics between the 6th and 19th centuries CE. It remains in animals and still spreads to humans in places as diverse as Mongolia, where it appeared in May, and New Mexico, where it surfaced last week. ...
Bacteria have developed ways to pump antibacterial drugs out of themselves, destroy antibiotics that successfully penetrate them, and otherwise evade antimicrobial molecules. Bacteria are capable of exchanging and collecting genes that encode these drug resistance and virulence mechanisms, thereby acquiring, in some cases, imperviousness to all antibiotics previously used to treat them. Unprecedented human travel and globalization have enabled bacteria from one place to take hold in another. ...
Between 1990 and 2019, 78% of major drug companies have reduced or eliminated antibiotic research. Some startups pursuing antibacterials have pivoted away from infectious disease research to survive. A genuinely novel class of antibacterial drugs, dissimilar in chemical structure to current types of antibiotics, has not been developed in more than three decades.
... To assist small companies in developing antibacterial drugs, a consortium of pharmaceutical companies recently established the AMR Action Fund. This entity plans to spend $1 billion to help bring two to four new antibiotics to the clinic by 2030. Moreover, it intends to build an alliance of stakeholders to encourage governments to create conditions favorable to sustainable antibacterial discovery and development.
A "Manhattan Project" to Fight Antibiotic-Resistant Bacteria
Organizations like CARB-X and the AMR Action Fund provide critical assistance in the battle against bacterial pathogens. Given that bringing a single antibiotic from concept to clinic costs $1 billion, and given the need for many new drugs, we must make much more significant investments. ...
11th Aug 2020 7:00 am RNS Positive interim safety review of XF-73 phase 2b
Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections
Brighton, United Kingdom - 11 August 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that address the global challenge of antimicrobial resistance (AMR), announces a positive interim safety review has been completed by an Independent Data Monitoring Committee (IDMC) of the Company's ongoing Phase 2b study of its lead asset XF-73 in the prevention of post-surgical bacterial infections.
Further to the announcement on 27 July 2020 detailing a US Food and Drug Administration approved clinical protocol amendment to the Phase 2b study, the IDMC has reviewed safety data from the first 75 cardiac surgery patients who have completed study treatment. Adverse event data, including safety laboratory results, incidence of post-operative infections, ear, nose, and throat examinations, as well as sense of smell tests were reviewed by the IDMC. Based on their evaluation, the IDMC has recommended that the study can continue without any modifications to the protocol. Recruitment into the study remains on track to complete by the end of 2020.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
"We are very pleased the IDMC has concluded that there are no safety concerns in the patients treated in the Phase 2b study to date and that the study can continue as planned. This is consistent with our previous experience of testing XF-73 in several clinical studies. We believe XF-73 nasal gel has the potential to become a well-tolerated, novel and effective treatment for the prevention of post-surgical Staphylococcal infections and represents a significant commercial opportunity. We are now two thirds of the way through the study and look forward to completing recruitment by the end of 2020."
The ongoing Phase 2b trial is a multi-centre, randomised, blinded, placebo-controlled study of multiple applications of a single concentration of XF-73 nasal gel to assess the microbiological effect of XF-73 on commensal Staphylococcal aureus nasal carriage in 125 patients scheduled for surgical procedures deemed to be at high risk of post-operative Staphylococcal aureus infection.
The Phase 2b study design is closely related to the successful 2016 clinical trial, which was funded by the National Institute of Allergy and Infectious Disease (part of the US National Institute of Health) and demonstrated the clinical efficacy of XF-73 versus placebo in reducing nasal Staphylococcus aureus carriage in healthy volunteers.
#BulletinBoardHeroes 4th August 2020 @ZaksTradersCafe video charting update.
Destiny Pharma #DEST
IDE Group #IDE
Oxford Biodynamics #OBD
Redx Pharma #REDX
UK Oil & Gas #UKOG
Good to see upward movement here, was wondering when this will start climbing. Not too well followed but I think the company has huge potential and will start to get noticed.
Might hold on to these babies.
Thanks to the following four posters on ADVFN for these useful DEST posts this week:
edmonda 27 Jul '20 - 08:27 - 114 of 133 0 3 0
"Good news today from the FDA on XF-73 trial requirements. The shortage of new antimicrobial agents to fight global threat of antimicrobial resistance has not suddenly gone away.
Prevent of these infections is crucial and detailed research just out from Dr Andy Smith at Equity Development valuing DEST shares at 197p vs 31p.
Free access to read note here : https://tinyurl.com/y5qo7468 "
fillipe 27 Jul '20 - 08:49 - 115 of 133 0 2 0
"Also today, finnCap reiterate a 250p target price.
I'm surprised this isn't flying, although guess that many folks are much aware of the company.
Wh1spa 29 Jul '20 - 10:18 - 118 of 133 0 2 0
"Well I've bought in today. Just 25,000 shares but will add in the near future. As soon as peeps jump off the Covid bandwagon and realise AMR is more of an underlying threat - coupled with the fact that novel drugs/ approaches are needed urgently then they will no doubt turn up. Glad to see recent fund set up - it's a shame it's taken this awful pandemic to make governments sit up and start to think on a preventative level."
GB904150 31 Jul '20 - 17:47 - 128 of 133 0 1 0
"Hi Wh1spa, what is the easiest way to find the NMS of a share?
I picked up some of these for the first time today.
Like the prudent use of cash, funded to Q4 2021, strong insider ownership, AMR focus, new AMR action fund. Seems the timing is good on a risk/reward basis with the phase 2b trials coming up."
new faces gla making the most of these prices next year is only a few months away
This has great potential, a promising in-demand treatment, well funded, good support from FDA.
I’ve tucked some away this morning for a longterm hold.